Showing results (31-40 of 37) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Blood|July 1, 1997
Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphomaR D Gascoyne, S A Adomat, S Krajewski, et al.Gynecologic Oncology|January 18, 2016
First application of the Automated QUantitative Analysis (AQUA) technique to quantify PTEN protein expression in ovarian cancer: A correlative study of NCIC CTG OV.16J I Weberpals, M S Amin, B E Chen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1997
Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapyW S Lofters, J L Pater, B Zee, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1997
The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapyJ L Pater, W S Lofters, B Zee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials GroupJ Latreille, J Pater, D Johnston, et al.Journal of the National Cancer Institute|October 13, 2010
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxelP Hoskins, I Vergote, A Cervantes, et al.Current Oncology (Toronto, Ont.)|October 5, 2011
Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspectiveA M Oza, V Castonguay, D Tsoref, et al.Pageof 4